arrow
R

Ronghui Yu

the first affiliated hospital of anhui medical university
H指数:26
被引数:2,209

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Stage-Dependent Prognostic Value of the Joint MASLD–NAFLD Fibrosis Score Phenotype Across the Cardiovascular–Kidney–Metabolic Syndrome Continuum: A Retrospective NHANES Cohort Analysis, 1999–2018

基于心血管-肾脏-代谢综合征连续体的MASLD-NAFLD纤维化评分联合表型的分期依赖性预后价值:一项回顾性NHANES队列分析,1999–2018

2026-09-150
OAAI
Ethanol Infusion of the Vein of Marshall in Catheter Ablation of Persistent Atrial Fibrillation in Patients with Mitral Valve Replacement

经Marshall静脉乙醇灌注在合并二尖瓣置换术患者的持续性心房颤动导管消融中的应用

2025-09-040
PRE
Predictive value of sudden cardiac death risk stratification for outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy

肥厚型心肌病患者导管消融术治疗房颤的预后中,心源性猝死风险分层的预测价值

2025-07-220
PRE
Ablation characteristics associated with steam pops in ablation index-guided radiofrequency ablation of atrial fibrillation

与射频消融术治疗心房颤动中蒸汽爆裂相关的消融特性

2025-04-080
PRE
Prospective randomized comparison between upgraded?2C3L? vs. PVI approach for catheter ablation of persistent atrial fibrillation: PROMPT-AF trial design
2023-06-019
OAAI
Risk Factors for Left Ventricular Thrombus Formation in Patients with Dilated Cardiomyopathy

扩张型心肌病患者左心室血栓形成的危险因素分析

2022-09-158
PRE
The safety of discontinuation of oral anticoagulation therapy after apparently successful atrial fibrillation ablation: a report from the Chinese Atrial Fibrillation Registry study

明显成功的房颤消融后停止口服抗凝治疗的安全性: 来自中国房颤注册研究的报告

2019-09-0551
OAAI